November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Talha Badar: Different aspects of TP53 mutated AML
Oct 1, 2024, 17:45

Talha Badar: Different aspects of TP53 mutated AML

Talha Badar shared a post on X:

“I will share our collaborative effort in looking at different aspects of TP53 mutated AML:

  1.  Impact of induction strategy on outcome 10.1002/ajh.26546
  2.  Transplant outcome 10.1038/s41375-023-01847-7
  3.  Racial disparities in treatment and outcomes 10.1002/cncr.34604
  4.  Impact of venetoclax addition to HMA on response and survival 10.1038/s41408-024-01000-2
  5.  Impact of ‘single’ vs ‘multi-hit’ TP53 10.3324/haematol.2024.285000

I can not thank enough to all the collaborators of Command Consortium.

Talha Badar: Different aspects of TP53 mutated AML

Impact of induction strategy on outcome We saw increased utilization of venetoclax based therapy in recent times. In terms of induction strategy, HMA+VEN showed favorable odd ratio in achieving response but had higher TRM. Median EFS and OS remains dismal in the range of 6-9 months. 10.1002/ajh.26546

Talha Badar: Different aspects of TP53 mutated AML

Transplant outcome.

Only 68/370 (18%) of patient were successfully bridge to allo-HCT. EFS and OS from time to allo-HCT was 12.4 and 24.5 mo

MRD/ TP53m status at alloHCT, intensity of conditioning was not predictive of outcome. Patient maintaining CR at D100 post alloHCT, occurrence of cGVHD suggestive of better outcome. 10.1038/s41375-023-01847-7

Talha Badar: Different aspects of TP53 mutated AML

Racial disparities in treatment and outcomes

Non-Hispanic black (NHB) had higher incidence of t-AML, co-mutations. While responses were comparable, NHB less likely to receive curative intent therapies including alloHCT; highlighting disparities in treatment of TP53m/high-risk AML. 10.1002/cncr.34604

Talha Badar: Different aspects of TP53 mutated AML

Impact of venetoclax addition to HMA on response and survival

  1. We observed high CR rates (35% vs. 18%)
  2. Extended DOR (15.6 vs. 7.93 months)
  3. high % of patient progressing toward allo-HCT (13% vs. 4%) with HMA + VEN compared to HMA, this did not translate in an improvement in OS.

Baseline characteristics, co-mutation patterns, or the presence of complex CG and MH TP53m comparable b/w 2 gps. 10.1038/s41408-024-01000-2

Talha Badar: Different aspects of TP53 mutated AML

Impact of ‘single’ vs ‘multi-hit’ TP53 Unlike low risk MDS we didn’t find differential impact on response and outcome b/w SH vs MH TP53 DOR, EFS and OS were comparable b/w SH and MH TP53

Allo-HCT associated with improve survival irrespective of mutation status. 10.3324/haematol.2024.285000

Talha Badar: Different aspects of TP53 mutated AML

Source: Talha Badar/X

More posts featuring Talha Badar on oncodaily.com

Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and . Over his career, he has actively contributed to clinical research and clinical trials.